Alignment Healthcare, Inc. (ALHC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong membership growth, revenue projections, and an optimistic outlook for 2026, with investments in automation and quality improvements. The Q&A section supports these with discussions on favorable SG&A variance, strong retention, and strategic investments, despite some uncertainties in competitive environments. The overall sentiment is positive, driven by strategic growth plans and financial health improvements.
Key Financial Performance
Health Plan Membership 229,600 members, representing growth of approximately 26% year-over-year. Growth driven by strong new member sales.
Total Revenue $994 million, increasing approximately 44% year-over-year. Growth supported by strong health plan membership growth.
Adjusted Gross Profit $127 million, increased by 58% year-over-year. Improvement driven by disciplined execution of clinical activities and lower inpatient admissions per 1,000 in the low 140s.
Consolidated MBR (Medical Benefit Ratio) 87.2%, an improvement of 120 basis points year-over-year. Improvement attributed to disciplined clinical execution and moderated growth in utilization trends.
Adjusted SG&A Ratio 9.6%, improved by 120 basis points year-over-year. Improvement driven by scalability of the operating platform and timing benefits in SG&A expenses.
Adjusted EBITDA $32 million, representing 240 basis points of margin expansion compared to the third quarter of 2024. Improvement driven by strong execution and scalability of operations.
Cash, Cash Equivalents, and Investments $644 million at the end of the third quarter. Increase due to timing of certain medical expense payments, which resulted in higher operating cash flow during the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Health plan membership: 229,600 members, representing a 26% year-over-year growth.
Revenue: $994 million, a 44% year-over-year increase.
Adjusted gross profit: $127 million, a 58% year-over-year increase.
Adjusted EBITDA: $32 million, surpassing guidance.
Geographic expansion: Strong performance in California, North Carolina, Nevada, and Texas. California HMO contract earned a 4-star rating for the ninth consecutive year. Two 5-star contracts in North Carolina and Nevada, and 4.5 stars in Texas in its first rating year.
Market share: Expected 20% year-over-year growth in membership for 2026, with a focus on markets with strong provider relationships.
Operational improvements: Investments in back-office automation, clinical engagement, AVA AI clinical stratification, and Stars durability.
Cost management: Adjusted SG&A ratio improved to 9.6%, a 120 basis points improvement year-over-year.
Strategic focus: Balancing membership growth and profitability objectives, leveraging care management capabilities to maintain stable benefits.
CMS transition: Adapting to CMS' new health outcomes reward system, focusing on clinical outcomes for vulnerable low-income seniors.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes: The transition to the excellent health outcomes for all reward (formerly Health Equity Index) by CMS introduces new criteria for health plans, which could pose challenges in maintaining high star ratings and associated funding advantages.
Medicare Advantage Industry Disruption: Continued disruption in the Medicare Advantage (MA) industry in 2026 could create uncertainties and challenges in maintaining growth and profitability.
Seasonal Utilization Impact: Higher medical utilization in the final months of the year, including the seasonal impact of the flu, could increase the MBR and affect profitability.
Part D Program Changes: Significant changes to the Part D program introduce uncertainties in utilization trends and margin assumptions, requiring careful management to meet financial targets.
Growth-Related Costs: Expected increase in SG&A expenses during the fourth quarter due to growth-related costs and timing of certain expenses could impact profitability.
Competitive Pressures: The need to balance membership growth and profitability objectives amidst competitive pressures in the Medicare Advantage market could strain resources and strategic execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EBITDA for 2025: The company expects to deliver $94 million of adjusted EBITDA at the midpoint of its guidance range for 2025, compared to the initial guidance of $47.5 million.
Stars Ratings and Future Implications: 100% of health plan members are in plans rated 4 stars or above for rating year 2026, payment year 2027. The company expects the improvement in the raw star score of its California HMO plan to set a solid foundation for rating year 2027 and payment year 2028. CMS' transition to the excellent health outcomes for all reward is expected to add cushion to the 4-star rating in California.
2026 Annual Enrollment Period (AEP) and Membership Growth: The company is taking a measured approach to balance membership growth and profitability objectives. It expects to grow at least 20% year-over-year in 2026, supported by early AEP results and a focus on matching seniors with the right products and growing in markets with strong provider relationships.
Revenue and Membership Guidance for 2025: For the full year 2025, revenue is expected to be in the range of $3.93 billion to $3.95 billion, with year-end membership guidance raised by 2,000 members at the midpoint. Fourth-quarter revenue is expected to range between $995 million and $1.01 billion, with health plan membership between 232,500 and 234,500 members.
Adjusted Gross Profit and MBR for 2025: The company updated its adjusted gross profit guidance to $479 million at the midpoint, reflecting an MBR of 87.9% and nearly 100 basis points of improvement year-over-year. Fourth-quarter adjusted gross profit is expected to range between $104 million and $113 million.
2026 Market Opportunities and Industry Disruption: The company anticipates incremental opportunities to gain market share in 2026 due to continued disruption in the Medicare Advantage industry, while also growing adjusted EBITDA year-over-year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How would you frame the market share opportunities from industry disruption in the context of California versus non-California markets?
A:John Kao expressed satisfaction with growth in California and highlighted leveraging 5-star ratings in North Carolina and Nevada. He emphasized the importance of product mix and high-performing provider networks. He also noted confidence in managing growth and scaling the clinical model effectively.
Q:What are your considerations around pursuing M&A or partnership opportunities on the vertical integration side to unlock MLR opportunities?
A:John Kao mentioned being discerning and careful about tuck-in opportunities, particularly related to supplemental benefits and ancillary captives. He highlighted potential margin improvement opportunities with minimal execution risk by starting or acquiring ancillary businesses like dental PPOs or behavioral HMOs.
Q:Can you remind us where you are in terms of risk sharing with physicians in California and how you see that evolving during 2026 and beyond?
A:John Kao stated that 65-70% of their business involves shared risk arrangements, particularly in Southern California. He noted improvements in clinical and financial outcomes due to taking on more UM components. He also mentioned a trend towards more shared risk business outside California and emphasized the benefits of direct provider visibility and control.
Q:Can you dimension the favorability with SG&A and where the reinvestment is going?
A:James Head noted a favorable SG&A variance of a few million dollars in Q3, with full-year guidance remaining at $385 million. Reinvestment is focused on automation, AI logic improvements, and productivity enhancements in clinical programs, aiming for benefits in 2026 and 2027.
Q:If you were to do less growth, would that empower your EBITDA bridge?
A:Michael Ha suggested that less growth could empower the EBITDA bridge due to fewer lower-margin new members. John Kao acknowledged the point but emphasized their focus on balanced growth and retention.
Q:Can you reconcile the commentary on raw Star ratings improvement versus the summary ratings?
A:John Kao clarified that their overall raw score increased significantly from 3.7 to 4.05 or 4.06. He acknowledged the complexity of Part C and Part D measures but emphasized the raw score improvement.
Q:How should we think about the brand investment going forward and its impact on member acquisition costs?
A:James Head and John Kao discussed a balanced approach to SG&A, with investments in brand, clinical infrastructure, and automation. John highlighted the opportunity to establish a strong brand for Alignment, focusing on serving seniors and showcasing the benefits of Medicare Advantage.
Q:Can you offer perspective on retention versus gross new adds for 2026?
A:John Kao reported strong gross adds and better-than-anticipated retention across the board, attributing success to investments in member experience.
Q:How does Alignment manage through Part D redesign despite having relatively low deductibles and co-pays?
A:John Kao emphasized consistency and market-specific strategies in benefit design. He noted stability in Part D benefits and a focus on quality and value creation for beneficiaries.
Q:What are your thoughts on the likelihood of a potential V29 and its implications?
A:John Kao speculated on potential changes related to HRAs and program integrity but doubted the implementation of encounter-based baselining for 2027. He emphasized the importance of trust in the program and eliminating gaming.
Q:What is your view on overall MA market growth in 2026?
A:John Kao noted that California typically grows slower than the industry average but expressed confidence in Alignment's growth and retention strategies amid market disruption.
Q:Are you seeing any behavioral changes from seniors regarding vaccine uptake this year?
A:James Head observed flu shot trends consistent with previous years, with a slight softness in Q3 but a pickup in October. He noted caution about seasonal flu impacts in Q4.
Q:How much of the investment spend is already captured in current spend versus what's new or incremental?
A:James Head stated that investments are being applied smartly across the enterprise without dramatic increases. He emphasized underwriting investments carefully and reinvesting in the platform and human capital.
Q:What percent of competing plans in your markets were commissionable last year compared to this year?
A:John Kao did not have specific data but noted that most plans are still paying commissions.
Q:Where are we on RADV, and how prepared is the organization?
A:James Head mentioned a pause due to the Humana case but expects CMS to pursue RADV. He expressed confidence in Alignment's compliance and documentation processes, emphasizing their prudent approach to risk adjustment.
Q:What is the makeup of lives coming onto your books during AEP?
A:John Kao stated that 80-85% of new members are switches, with no particular concentration from any payer. He noted consistency across geographies.
Q:How do you think about a potentially more competitive environment post-V28?
A:John Kao emphasized Alignment's ability to manage care and control costs, positioning them well for a tight reimbursement environment post-V28. He highlighted the importance of quality care and cost management.
Q:How is replicability translating into MLR performance and margins in newer markets?
A:John Kao expressed confidence in replicating their model in new markets, emphasizing systematic approaches and best practices. He highlighted their ability to scale shared services and care models effectively.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about the percentage of competing plans in their markets that were commissionable last year compared to this year, stating they did not have specific data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEP core
AEP plan
AI improvement
AI stratification
AVA AI
CEO Head
CMS mission
CMS transition
California HMO
California change
California commitment
Carolina Nevada
HMO plan
Health plan
Index cushion
Medicare solution
Nevada star
Stars durability
Texas rating
ability cost
ability risk
activity season
admission power
alignment quality
approach membership
approach objective
approach year
architecture resource
automation engagement
average consistency
benefit product
bonus factor
capability capacity
capacity benefit
care improvement
center date
change health
change measure
competitor midpoint
end result
provider relationship
quality outcome
rating payment
replicability
ALHC Transcript
Alignment Healthcare, Inc. (ALHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Alignment Healthcare, Inc. (ALHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Alignment Healthcare, Inc. (ALHC) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call summary reveals strong financial metrics and optimistic guidance, with significant revenue growth and market expansion plans. Despite some concerns over inpatient issues, management has addressed these, and the guidance reflects confidence. The Q&A section indicates that analysts are satisfied with management's responses, and there is optimism about the company's strategic plans, including market expansion and operational efficiency improvements. Given the market cap of approximately $1.5 billion, these positive factors are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Alignment Healthcare, Inc. (ALHC) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call summary and Q&A indicate strong financial performance with increased EBITDA and revenue, positive free cash flow, and improved operational efficiency. While SG&A increased, it declined as a percentage of revenue. Optimistic guidance and strategic market positioning, including AI investments and strong provider relationships, further support a positive outlook. The company's low exposure to risk model rebasing and proactive approach to regulatory changes enhance confidence. The market cap suggests moderate sensitivity to these positive developments, leading to a likely positive stock price movement over the next two weeks.
ALHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
